Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

This study is testing a combination of two immunotherapy drugs — balstilimab and botensilimab — as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that has spread to other parts of the body. These drugs help the immune system find and attack cancer cells. **You may be eligible if:** - You are 18 years or older - You have been diagnosed with metastatic non-small cell lung cancer and have not yet received treatment for metastatic disease - Your tumor does not have EGFR mutations or ALK rearrangements (specific genetic changes) - Your physical performance (ECOG score) is 0 or 1 - Your life expectancy is at least 3 months - Your cancer shows measurable disease on scans - Your liver, kidney, and blood counts are within acceptable ranges **You may NOT be eligible if:** - You have EGFR mutations or ALK rearrangements (other targeted therapies may be more appropriate) - You have already received treatment for metastatic disease - You have severe autoimmune disease or are on immune-suppressing medications - Your prior treatment relapse occurred within 6 months of finishing neoadjuvant or adjuvant therapy Talk to your doctor to see if this trial is right for you.